Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges
Por:
Saini KS, Svane IM, Juan-Otero M, Barlesi F and André F
Publicada:
1 ene 2022
Ahead of Print:
1 dic 2021
Resumen:
Filiaciones:
Saini KS:
Labcorp Drug Development Inc., Princeton, NJ, USA
Svane IM:
National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
Juan-Otero M:
Department of Immunology, Hospital Clinic, IDIBAPS, Immunotherapy platform Hospital Sant Joan de Déu, Universidad de Barcelona, Barcelona, Spain
Barlesi F:
Department of Medical Oncology, Institut Gustave Roussy, Villejuif
Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France
André F:
Institut Gustave Roussy, INSERM UMR981, Université Paris Saclay, Paris, France
|